Goldman Sachs Maintains Sell Rating for PTC Therapeutics, Raises PT to $50.

miércoles, 5 de noviembre de 2025, 12:01 pm ET1 min de lectura
PTCT--

Goldman Sachs Maintains Sell Rating for PTC Therapeutics, Raises PT to $50.

Goldman Sachs Maintains Sell Rating for PTC Therapeutics, Raises PT to $50.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios